NAD keeps abreast of misleading claims
This article was originally published in The Tan Sheet
Executive Summary
Testimonial evidence offered in support of CP Nutritionals' claims for Full & Firm breast enhancement capsules is "inadequate and insufficient to substantiate the underlying claims of product performance and safety," Council of Better Business Bureaus National Advertising Division concludes in September Case Reports. Wellquest International challenged claims that Full & Firm capsules, which contain "eight natural herbs," promote "dramatic breast growth so quick, most women actually 'feel' their breasts growing" and "the longer you take them, the more they'll expand your breast tissue." Although CP Nutritionals defended its ads, firm has halted all promotions and "been put into receivership by the Arizona Superior Court of Maricopa County by action of the Attorney General of Arizona," NAD notes...
You may also be interested in...
Isis Breast Enhancement System Safety, Efficacy Questioned By FTC
Vital Dynamics promoted its Isis Breast Enhancement System as free of side effects after receiving "hundreds of reports of negative side effects," according to a Federal Trade Commission complaint
NAD busts Shoreline
Latavi breast enhancement product marketer Shoreline Enterprises has "failed to provide a substantive written response" to defend claims for its "all-natural" supplement, National Advertising Division says in recent Case Reports, referring issue to FTC. Wellquest International challenged print, radio ads for Latavi, which claims to "enlarge and tone your breasts and increase the size of your breasts at least two cup sizes, guaranteed." In response, Shoreline claimed its product substantiation is proprietary and would not submit written documentation to CBBB division. Wellquest recently initiated a similar case against CP Nutritionals (1"The Tan Sheet" Sept. 23, 2002, p. 18)...
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.